Key Finding:
Mutations in HRAS are associated with poor outcomes and higher MAPK activation, PD-L1 levels, tumor mutational burden, and IFN scores in head and neck squamous cell carcinomas.
Publications
Clinicopathologic characteristics of HRAS mutant head and neck squamous cell carcinoma (HNSCC).
– Caris Life Sciences
Download Publication